Navigation Links
Rheumatoid Arthritis: World Drug Market 2011-2021
Date:11/2/2011

reatments

11.4 Improvements Needed in RA Treatments

11.5 Future Rheumatoid Arthritis Treatments: R&D Efforts Promising

11.6 The RA Treatments Sector: Looking into the Future Confidently

List of Tables

Table 2.1 Diseases with Symptoms Similar to RA, 2011

Table 3.1 Main Treatments for RA, 2011

Table 3.2 Revenues ($bn) for Main Biologics (All Inflammatory Indications), 2010

Table 4.1 The Global RA Drug Market Forecast ($bn), 2010-2021

Table 4.2 Total NSAIDs Market for RA Treatments ($bn), 2010-2021

Table 4.3 Other Non-Biologics Market for RA Treatments ($bn), 2010-2021

Table 4.4 Total Revenue for Main Biologics for All Inflammatory Conditions: Market Forecast ($bn), 2010-2021

Table 4.5 Estimated Contribution by Biologics for RA: Market Forecast ($bn), 2010-2021 

Table 4.6 RA Treatments: Forecasts for Submarkets ($bn), 2010-2021

Table 4.7 World Rheumatoid Arthritis Treatments by Submarket ($bn), 2010, 2015 and 2021

Table 5.1 World Celebrex Revenue Forecast ($bn), 2010-2021 

Table 5.2 World Arcoxia Revenue Forecast ($bn), 2010-2021

Table 5.3 NSAID Market Forecasts for RA Treatment ($bn), 2010-2021

Table 5.4 World Humira Revenue Forecast ($bn), 2010-2021

Table 5.5 World Remicade Revenue Forecast ($bn), 2010-2021

Table 5.6 World Enbrel Revenue Forecast ($bn), 2010-2021

Table 5.7 World MabThera Revenue Forecast ($bn), 2010-2021

Table 5.8 World Orencia Revenue Forecast ($bn), 2010-2021

Table 5.9 World Actemra Revenue Forecast ($bn), 2010-2021

Table 5.10 World Cimzia Revenue Forecast ($bn), 2010-2021

Table 5.11 Biologics: Revenue Forecasts ($bn), 2010-2021

Table 6.1 R&D Pipeline: NSAIDs and Painkillers, 2011

Table 6.2 R&D Pipeline: Corticosteroids, 2011

Table 6.3 R&D Pipeline: Biologics, 2011

Table 7.1 Leading National Revenues ($bn) and Market
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
2. Rheumatoid Arthritis Market Forecast
3. HYCOR Broadens Diagnostic Offerings, Announces Agreements to License Biomarkers for Celiac Disease and Rheumatoid Arthritis
4. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
5. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6
6. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
7. Exagen Diagnostics Inc. Partners with Medco Research Institute® to Develop NIMBLE Personalized Medicine Program for Rheumatoid Arthritis Patients
8. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
9. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
10. Reportlinker Adds U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
11. Reportlinker Adds Epidemiology: Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
(Date:9/2/2015)... -- Elekta, a global cancer management company, will ... 6:30-8:30 p.m., at Elekta,s North American headquarters in ... will feature Professional BMX athlete, Josh Perry , who ... Leksell Gamma Knife®, Elekta,s radiosurgery system for treating brain disorders. ... diagnosed in Georgia in 2015 and ...
(Date:9/2/2015)... Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) ... to implement a buccal cannabis co-development arrangement ... has been formalized. Generex and ... and Technology Licensing Agreement.  Pursuant to the ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 2Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 3Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3
... , , INDIANAPOLIS, Nov. 16 ... Chairman, President and Chief Executive Officer John Lechleiter today presented ... check represents the contributions of Lilly,s U.S. employees and retirees ... funds were raised for the Central Indiana chapter and other ...
... , - Used during coronary angioplasty plus stenting, in ... new reversible blood thinner did not have a significantly ... all-cause mortality, heart attack and need for new procedures ... drug significantly lessened the risk for two pre-specified single ...
Cached Medicine Technology:Lilly Surpasses United Way 2009 Campaign Goal 2Lilly Surpasses United Way 2009 Campaign Goal 3American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 2American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 3
(Date:9/2/2015)... ... September 02, 2015 , ... ... investment, announced the two leaders who will deliver keynote presentations at the upcoming ... the Mandarin Oriental Hotel in Boston. , Larry Renfro, CEO of Optum, will ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Blincyto® (blinatumomab) – in the news recently following a decision by the Centers ... patients – is likely to average approximately $71,000 or roughly 40% of its ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Officer following the departure of Kristen Dietz, former Chief Operations Officer. Shaun ... the following statement welcoming Mr. Salot: “ Stanley H. Salot Jr , our ...
(Date:9/2/2015)... ... 2015 , ... Good health and a good cause paired up at The ... BCBSNJ) donated $11,000 to the New Jersey Golf Foundation through its Healthy Steps Challenge. ... The Barclays, Horizon BCBSNJ challenged PGA TOUR golfer and NJ native Morgan Hoffmann to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... at Children's Healthcare of Atlanta to help support childhood cancer research. On ... upcoming WSB Radio Care-A-Thon , which is the fund-raising event DoMyOwnPestControl.com sponsors ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:Healtec® Announces Executive Leadership Change 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2
... a gene that appears to increase a person,s risk ... of the disease. The gene, abbreviated as MTHFD1L, is ... association study. Details are published September 23 in the ... of researchers was led by Margaret A. Pericak-Vance, PhD, ...
... of motorcycle crashes were 1.5 times more likely to ... though many more of the African-American victims were wearing ... new study by Johns Hopkins researchers. Results of ... August issue of the American Journal of Surgery ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Sept. 23 ... use and texting soared in the space of three years, ... alone caused more than 16,000 deaths in car accidents from ... cell phones and texting while driving rose 28 percent in ...
... Cancer Center have discovered a new cell signaling pathway ... when defective, helps promote the formation of several major ... The new pathway, part of a global DNA damage ... are known to cause cancer because, unchecked, they can ...
... Nursing professor, Dr. Diane Doran, was awarded more than ... safety of over 900,000 Canadians who receive health care ... Patient Safety Institute and its partners announced today the ... of Canada,s leading healthcare researchers. The selected research team ...
... a well-crafted football play designed to block the opposing ... constantly executes complex ,plays, or sequences of events to ... Scientists at the University of Rochester Medical Center recently ... the unwanted enlargement of the heart and a well-known ...
Cached Medicine News:Health News:Team of researchers finds possible new genetic risk for Alzheimer's disease 2Health News:Black motorcyclists -- even in helmets -- more likely to die in crashes 2Health News:Texting Taking a Deadly Toll on Roads 2Health News:Texting Taking a Deadly Toll on Roads 3Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 2Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 3Health News:$1 million awarded to Bloomberg Faculty of Nursing-led research team 2Health News:Molecular 'playbook' for halting heart failure risk factor uncovered 2
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
... The DRS 2000, a uniquely intelligent system, ... its space saving, 2-level design. Up to 27 ... to give you the flexibility to tailor your ... lab. Two start stations allow for continuous loading; ...
... latest from the leader in automatic slide ... modern approach to slide staining, ending messy ... blood smears, bone marrow and other body ... Aerospray stainer becomes a superb cytocentrifuge with ...
Medicine Products: